AJ Vaccines loses ground in Denmark and Europe

Vaccine manufacturer AJ Vaccines came out of 2019 with a significant dive on its top and bottom line, but the company expects tailwind from selling its polio vaccine, which was approved earlier this year.

Photo: AJ Vaccines

Non-European markets still constitute a major part of sales at AJ Vaccines, after the vaccine manufacturer, established three years ago, has had to note a decline in sales on the Danish home market as well as on other European markets, shows the company's 2019 report.

In Denmark, around one third of the revenue was shaved off from 2018 to 2019 with it landing on DKK 56m (USD 8.8m). For the rest of Europe, sales went from DKK 194m to DKK 109m.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles